

Applicant : Mounji G. Bawendi et al.
Serial No. : 09/832,959
Filed : April 12, 2001
Page : 8

Attorney's Docket No.: 01997-273003

REMARKS

Claims 46 and 47 have been amended. New claims 49-95 have been added. Support for the amendments and new claims can be found throughout the specification. No new matter has been added.

Attached is a marked-up version of the changes being made by the current amendment.

Applicants ask that all claims be examined. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 6-29-01


Harold H. Fox
Reg. No. 41, 498

Fish & Richardson P.C.
601 Thirteenth Street, NW
Washington, DC 20005
Telephone: (202) 783-5070
Facsimile: (202) 783-2331

Version with markings to show changes made

In the claims:

Claim 46 and 47 have been amended as follows:

46. (Amended) A method of detecting an interaction between a **[compound]** composition and a biological **[target]** moiety comprising **[the steps of]**:
providing a composition capable of a characteristic spectral emission, the
composition comprising a compound; a semiconductor nanocrystal associated
with the compound **[wherein said spectral emission is tunable to a desired
wavelength by controlling the size of the nanocrystal, and wherein said
emission provides information about a biological state or event]**; and
allowing a sample comprising a biological **[target]** moiety to interact with the
composition; and
detecting the interaction of the biological **[target]** moiety by monitoring the
spectral emission of the composition.

47. (Amended) The method of claim **[47]** 46, wherein monitoring the spectral
emission **[is associated with]** occurs in assays selected from the group consisting of:
immunochemistry, immunocytochemistry, immunobiology, immunofluorescence, DNA
sequence analysis, fluorescence resonance energy transfer, flow cytometry, fluorescence
activated cell sorting, diagnostics in biological systems, and high-throughput screening.